Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Classical hematology 2Gynecologic 1

Conditions

Venous Thromboembolism 1Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery 1Neoplasms 1Embolism 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Rivaroxaban × 1 year × Clear all
NCT04618913 2026-05-26

VICTORIE

Pfizer

Active not recruiting
1 enrolled
Classical hematology

Embolism, Neoplasms, Venous Thromboembolism

NCT06220123 2025-07-22

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Beijing Suncadia Pharmaceuticals Co., Ltd

Phase 2 Completed
225 enrolled
Classical hematologyGynecologic

Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Data powered by HemOnc (CC BY 4.0) Colophon âš¡